Mesa Laboratories Inc /Co/ (MLAB, Life Sciences Tools & Services) Stock Valuation & Fair Value Quality business with a solid forward outlook
Mesa Laboratories Inc /Co/ (MLAB, Life Sciences Tools & Services) trades at a blended P/E of 11.8, about 53% below its historical normal valuation, with a forward growth estimate of -2.8%. Analysts' one-year estimates have been hit 27% of the time. Priced at its historical normal P/E of 25.2 on the same blended earnings, the 2026-09-18 close of $126.54 corresponds to about $271 a share. This is a valuation reference, not a price target.
Valuation flags
- Negative growth forecast
Verdict history
tickerseer's rating has been quality business with a solid forward outlook since 2026-08-07.
Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.
Selected weeks: the first, the latest, and the cheapest and dearest.
Frequently asked questions
Is Mesa Laboratories Inc /Co/ stock overvalued?
At a blended P/E of 11.8 versus its historical normal P/E of 25.2, Mesa Laboratories Inc /Co/ trades about 53% below its typical valuation. tickerseer currently rates it quality business with a solid forward outlook.
What is Mesa Laboratories Inc /Co/'s fair value and PEG?
Mesa Laboratories Inc /Co/ trades at a blended P/E of 11.8 against a historical normal P/E of 25.2, a forward growth estimate of -2.8%. Priced at its historical normal P/E of 25.2 on the same blended earnings, the 2026-09-18 close of $126.54 corresponds to about $271 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Mesa Laboratories Inc /Co/ changed?
tickerseer's rating has been quality business with a solid forward outlook since 2026-08-07.
Industry: Life Sciences Tools & Services. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.